Home Magazines Editors-in-Chief FAQs Contact Us

Quality evaluation of artemether/lumefantrine products sold in community pharmacies in lagos state, south-western Nigeria

Journal of Analytical & Pharmaceutical Research
Sikiru Olatunji Usman, Olufunmilayo Atobatele, AbdulWasiu Busari, Ibrahim Adekunle Oreagba and Esther Oluwatoyin Agbaje

PDF Full Text


Background: Artemether-lumefantrine (AL) is a first line artemisinin-based combination therapy (ACT) recommended by the National guideline for the treatment of malaria in Nigeria. However, numerous brands, with price discrepancy, abound in Nigerian drug market and some of them may be substandard, thereby, predisposing consumers to the problems of ineffectively treated malaria and drug resistance. Objective: This study was aimed at evaluating the price variations and quality of artemether/ lumefantrine products that are being sold in Community Pharmacies in Lagos State, South Western Nigeria. Methods: By means of a well-structured questionnaire, information about the selling price of different brands of AL was obtained from 20 community pharmacies in different local government areas of Lagos State. Eleven NAFDAC registered brands of the antimalarial drug were randomly selected based on low and high selling price and the strength of artemether and lumefantrine in each brand was determined using High Performance Liquid Chromatography (HPLC) to evaluate their quality.
Results: The average selling price range of AL (80/480mg) in all the Pharmacies was 326 to 1386 naira. Only five out of the eleven brands of AL (80/480mg) met the active ingredients strength specifications. The rest were substandard.
Conclusion: Some brands of artemether/lumefantrine that are being sold in Nigerian Community Pharmacies are substandard. This may cause problems of malaria treatment failure and drug resistance. NAFDAC should engage in post-marketing evaluation of registered b


artemether/lumefantrine, quality, Nigeria